Biotech Networks

LABN Trending News: Celcuity’s shares rally after ESMO readouts; Disc Medicine’s $220M stock sale https://lnkd.in/g5HuN38t Plus, news about Novo Nordisk, Amgen, AstraZeneca, Viridian Therapeutics, Alto Neuroscience and Siren Biotechnology: Celcuity’s stock soars after ESMO readouts in breast cancer: After Roche presented its #ESMO25 readout for giredestrant … Click here to [...]

BCBN Trending News: Point32Health to eliminate 250 jobs in second workforce reduction this year https://lnkd.in/g_8RXYR7 The layoffs are part of an effort to curb administrative costs as insurers report significant financial losses. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks [...]

PNBN Trending News: Philadelphia life sciences sector cuts nearly 1,000 jobs in 2025 as investor caution grows https://lnkd.in/gB7SuAAZ Philadelphia’s life sciences sector is facing a wave of job cuts, with nearly 1,000 positions eliminated this year alone. Find out which companies have been affected and what’s driving this trend. Click here to view [...]

WOBN Trending News: Digital health company raises $28 million after move to Bellevue https://lnkd.in/gFSSBeXb The 10-year-old company aims expand its services and grow its sales and business development teams. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks Click here [...]

DCBN Trending News: Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma https://lnkd.in/gum4Edhv WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY #ESMO25–Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced PDAC Click here to view original post Click Here to Publish/Feature Your [...]

NCBN Trending News: BioAgilytix Makes Multi-Million-Dollar Investments in LC/MS Capabilities https://lnkd.in/gKffNCb4 By harmonizing our platforms and processes, BioAgilytix says it can ensure that its customers can move assays efficiently between sites and trust that the same standards of excellence are maintained across regions. The post BioAgilytix [...]

PNBN Trending News: STAT+: Pharmalittle: We’re reading about ESMO cancer trial results, warnings from Moderna co-founder, and more https://lnkd.in/gExtJgwW Patients with an aggressive form of breast cancer will likely have new treatment options after AstraZeneca and Gilead presented successful trial results Click here to view original post Click Here to Publish/Feature Your Company or [...]

BCBN Trending News: Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25 https://lnkd.in/gbmHXSKN NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a [...]

LABN Trending News: Amgen, AZ’s Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent https://lnkd.in/gupHUFYu The FDA has endorsed Amgen and AstraZeneca’s Tezspire as an add-on maintenance treatment for patients age 12 and older with chronic rhinosinusitis with nasal polyps. It is the second indication for Tezspire, which was originally [...]

SFBN Trending News: STAT+: At ESMO, AstraZeneca, Gilead square off in triple-negative breast cancer https://lnkd.in/gEPnV3iq BERLIN — Patients with a highly aggressive form of breast cancer will likely have new treatment options for the first time in years after AstraZeneca and Gilead Sciences both presented successful trial results here Sunday, [...]